A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-15. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
=== Regulation of expression === EPCIP is expressed during blastocyst, fetus, and adult states of human development. It is overexpressed during some tumor states, including pancreatic, gastrointestinal, germ cell, and glioma tumors.
=== Fentanyl analogs === Fentanyl analogs are types of fentanyl with various chemical modifications on any number of positions of the molecule, but still maintain, or even exceed, its pharmacological effects. Many fentanyl analogs are termed "designer drugs" because they are synthesized solely to be used illicitly. Carfentanil, a fentanyl analog, has an additional methyl ester group attached to the 4 position. Carfentanil is 20–30 times as potent as fentanyl and is common in the illicit drug chain. The drug is commonly used to tranquilize elephants and other large animals.
Dyspnea on exertion Peripheral edema and ascites Pericardial effusion Arrhythmias (secondary to disruption of the normal electrical system of the heart) Atrial arrhythmias (such as atrial fibrillation) First/second degree heart blocks Syncope Elevated neck veins and jugular venous pressure Myocardial ischemia/angina (secondary to amyloid deposition in the coronary arteries of the heart) Myocardial oxygen demand is increased in patients with cardiac amyloidosis, regardless of changes to coronary perfusion. For patients with light-chain amyloidosis, there can be depositions of amyloid into numerous different organs. Deposition of amyloid into other organs makes the diagnosis of cardiac amyloidosis difficult as these extracardiac manifestations mask the diagnosis. Extracardiac manifestations include:
Meanwhile, according to 2013 European Society of Cardiology (ESC) guidelines, a loop diuretic can only replace thiazide-type diuretics if there is renal impairment (Creatinine of more than 1.5 mg/dL or estimated glomerular filtration rate (eGFR) of less 30 mL/min/1.73 m2 due to lack of long term cardiovascular outcome data and appropriate dosing regimen of its use. The 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines stated that diuretics should not be used to treat acute kidney injury, except for the management of volume overload. Diuretics has not shown any benefits of preventing or treating acute kidney injury. They are also sometimes used in the management of severe hypercalcemia in combination with adequate rehydration.
Sources: en.wikipedia.org
==== Silver alloy – synergistic oxidation of carbon monoxide ==== Au-Ag alloy nanoparticles have been shown to have a synergistic effect on the oxidation of carbon monoxide (CO). On its own, each pure-metal nanoparticle shows very poor catalytic activity for CO oxidation; together, the catalytic properties are greatly enhanced. It is proposed that the gold acts as a strong binding agent for the oxygen atom and the silver serves as a strong oxidizing catalyst, although the exact mechanism is still not completely understood. When synthesized in an Au/Ag ratio from 3:1 to 10:1, the alloyed nanoparticles showed complete conversion when 1% CO was fed in air at ambient temperature. The size of the alloyed particles did not play a big role in the catalytic ability. It is well known that gold nanoparticles only show catalytic properties for CO when they are ~3 nm in size, but alloyed particles up to 30 nm demonstrated excellent catalytic activity – catalytic activity better than that of gold nanoparticles on active support such as TiO2, Fe2O3, etc.
Although Germans, Americans and Soviets experimented with small liquid-fuel rockets before World War II, launching satellites and humans into space required the development of larger ballistic missiles such as Wernher von Braun's Aggregat-4 (A-4), which became known as the Vergeltungswaffe 2 (V-2) developed by Nazi Germany to bomb the Allies in the war. After the war, both the US and USSR acquired custody of German rocket development assets which they used to leverage the development of their own missiles. Public interest in space flight was first aroused in October 1951 when the Soviet rocketry engineer Mikhail Tikhonravov published "Flight to the Moon" in the newspaper Pionerskaya pravda for young readers. He described a two-person interplanetary spaceship of the future and the industrial and technological processes required to create it. He ended the short article with a clear forecast of the future: "We do not have long to wait. We can assume that the bold dream of Konstantin Tsiolkovsky will be realized within the next 10 to 15 years." From March 1952 to April 1954, the US Collier's magazine reacted with a series of seven articles Man Will Conquer Space Soon! detailing Wernher von Braun's plans for crewed spaceflight. In March 1955, Disneyland's animated episode "Man in Space" which was broadcast on US television with an audience of about 40 million people, eventually fired the public enthusiasm for space travel and raised government interest, both in the US and USSR.
These are isostructural to the respective halides except for lithium cyanide, indicating that the cyanide ions may rotate freely. Ternary alkali metal halide oxides, such as Na3ClO, K3BrO (yellow), Na4Br2O, Na4I2O, and K4Br2O, are also known. The polyhalides are rather unstable, although those of rubidium and caesium are greatly stabilised by the feeble polarising power of these extremely large cations.
In 2007, the Alcohol and Tobacco Tax and Trade Bureau (TTB) effectively lifted the long-standing absinthe ban, and it has since approved many brands for sale in the US market. This was made possible partly through the TTB's clarification of the Food and Drug Administration's (FDA) thujone content regulations, which specify that finished food and beverages that contain Artemisia species must be thujone-free. In this context, the TTB considers a product thujone-free if the thujone content is less than 10 ppm (equal to 10 mg/kg). This is verified through the use of gas chromatography–mass spectrometry. The brands Kübler and Lucid and their lawyers did most of the work to get absinthe legalized in the U.S., over the 2004–2007 time period. In the U.S., 5 March sometimes is referred to as "National Absinthe Day", as it was the day the 95-year ban on absinthe was finally lifted. The import, distribution, and sale of absinthe are permitted subject to the following restrictions:
He raised approximately $850,000 by February, enough money to fund the somatostatin research projects. By August 1977, the research teams managed to create the first bacterium capable of synthesizing somatostatin. This was the proof of concept that the fledgling company sought. On December 2, 1977, Swanson and the scientists held a press conference announcing their findings. Following their success with the proof of concept, Swanson then directed the scientists to pursue the creation of a bacterium that synthesized human insulin. Two other scientific teams were already attempting to carry out such a project, but Swanson moved quickly to ensure that they synthesized it first. By early 1978, his priorities were to obtain a lab space for the scientists, corporate contracts, and more funding for Genentech. In order to attract the best scientists, Swanson, with the assistance of Boyer, tried to create an attractive environment for academic scientists. It was because of this that scientists at Genentech were allowed to publish their findings in scientific journals. The restriction was that they could publish only after the appropriate patents had already been filed. By February 1978, Swanson leased a 10,000-square-foot section of an airfreight warehouse, which would serve as Genentech's first lab space. Later that year, Swanson also secured a partnership with Eli Lilly; Genentech would receive $50,000 a month to pursue the human insulin project.
Sources: en.wikipedia.org
=== Sleeping sickness treatment === The drug was registered for the treatment of gambiense sleeping sickness on 28 November 1990. However, in 1995 Aventis (now Sanofi-Aventis) stopped producing the drug, whose main market was African countries, because it did not make a profit. In 2001, Aventis and the WHO formed a five-year partnership, during which more than 320,000 vials of pentamidine, over 420,000 vials of melarsoprol, and over 200,000 bottles of eflornithine were produced by Aventis, to be given to the WHO and distributed by the association Médecins sans Frontières (also known as Doctors Without Borders) in countries where sleeping sickness is endemic. According to Médecins sans Frontières, this only happened after "years of international pressure," and coinciding with the period when media attention was generated because of the launch of another eflornithine-based product (Vaniqa, for the prevention of facial-hair in women), while its life-saving formulation (for sleeping sickness) was not being produced.
On July 16, 2015, Universal Pictures announced that Kevin Hart: What Now?, a stand-up comedy film featuring a performance of Hart's What Now? Tour, would be theatrically released in the United States on October 14, 2016. The show was filmed live on August 30, 2015, in front of 53,000 people, at Philadelphia's Lincoln Financial Field. In 2025, Hart performed as a headliner in Saudi Arabia's Riyadh Comedy Festival, an event taking place from September 26 to October 9. The comedy festival overlaps with the seventh anniversary of the assassination of Jamal Khashoggi, prompting Joey Shea, Saudi Arabia researcher at Human Rights Watch, to say in a statement that the Saudi government is using the comedy festival to whitewash its human rights abuses. Hart has performed in the region before, the first time taking place in January, 2023.
In contrast to the open equilibrium scenario above, many swimming pools are managed by addition of sodium bicarbonate (NaHCO3) to the concentration of about 2 mmol/L as a buffer, then control of pH through use of HCl, NaHSO4, Na2CO3, NaOH or chlorine formulations that are acidic or basic. In this situation, dissolved inorganic carbon (total inorganic carbon) is far from equilibrium with atmospheric CO2. Progress towards equilibrium through outgassing of CO2 is slowed by
Treatments for the plastic repair of a broken nose are first mentioned in the Edwin Smith Papyrus, a transcription of text dated to the Old Kingdom from 3000 to 2500 BCE. The Ebers Papyrus (c. 1550 BC), an Ancient Egyptian medical papyrus, describes rhinoplasty as the plastic surgical operation for reconstructing a nose destroyed by rhinectomy. Such a mutilation was inflicted as a criminal, religious, political, and military punishment in that time and culture. Rhinoplasty techniques are described in the ancient Indian text Sushruta samhita by Sushruta, where a nose is reconstructed by using a flap of skin from the cheek. During the Roman Empire (27 BC – 476 AD) the encyclopaedist Aulus Cornelius Celsus (c. 25 BC – 50 AD) published the 8-tome De Medicina (On Medicine, c. 14 AD), which described plastic surgery techniques and procedures for the correction and the reconstruction of the nose and other body parts. At the Byzantine Roman court of the Emperor Julian the Apostate (331–363 AD), the royal physician Oribasius (c. 320–400 AD) published the 70-volume Synagogue Medicae (Medical Compilations, 4th century AD), which described facial-defect reconstructions that featured loose sutures that permitted a surgical wound to heal without distorting the facial flesh; how to clean the bone exposed in a wound; debridement, how to remove damaged tissue to forestall infection and so accelerate healing of the wound; and how to use autologous skin flaps to repair damaged cheeks, eyebrows, lips, and nose, to restore the patient's normal visage.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.